SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong

被引:9
作者
Lee, Chi-Ho [1 ,2 ]
Mak, Lung-Yi [1 ,3 ]
Tang, Eric Ho-Man [4 ]
Lui, David Tak-Wai [1 ]
Mak, Jimmy Ho-Cheung [1 ]
Li, Lanlan [4 ]
Wu, Tingting [4 ]
Chan, Wing Lok [5 ]
Yuen, Man-Fung [1 ,3 ]
Lam, Karen Siu-Ling [1 ,2 ]
Wong, Carlos King Ho [4 ,6 ,7 ,8 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China
[3] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China
[4] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[5] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Clin Oncol, Hong Kong, Peoples R China
[6] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[7] Lab Data Discovery Hlth D24H, Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
[8] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Pokfulam, Rm 1-01,1-F,Jockey Club AQ5 Bldg Interdisciplinary, Hong Kong, Peoples R China
关键词
FATTY LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; MELLITUS; POPULATION; INHIBITORS; FIBROSIS; SYSTEM; VIRUS;
D O I
10.1097/HEP.0000000000000404
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: Type 2 diabetes (T2D) and chronic hepatitis B infection (CHB) are risk factors of HCC. Sodium glucose co-transporter 2 inhibitors (SGLT2i) inhibit HCC oncogenesis in preclinical studies. However, clinical studies are lacking. This study aimed to evaluate the impact of SGLT2i use on incident HCC using a territory-wide cohort of exclusively patients with co-existing T2D and CHB. Approach and Results: Patients with co-existing T2D and CHB between 2015 and 2020 were identified from the representative electronic database of the Hong Kong Hospital Authority. Patients with and without SGLT2i use were 1:1 matched by propensity score for their demographics, biochemistry results, liver-related characteristics, and background medications. Cox proportional hazards regression model was used to assess the association between SGLT2i use and incident HCC. A total of 2,000 patients with co-existing T2D and CHB (1,000 in each SGLT2i and non-SGLT2i group; 79.7% on anti-HBV therapy at baseline) were included after propensity-score matching. Over a follow-up of 3,704 person-years, the incidence rates of HCC were 1.39 and 2.52 cases per 100 person-year in SGLT2i and non-SGLT2i groups, respectively. SGLT2i use was associated with a significantly lower risk of incident HCC (HR 0.54, 95%CI: 0.33-0.88, p=0.013). The association remained similar regardless of sex, age, glycemic control, diabetes duration, presence of cirrhosis and hepatic steatosis, timing of anti-HBV therapy, and background antidiabetic agents including dipeptidyl peptidase-4 inhibitors, insulin, or glitazones (all p interaction>0.05). Conclusions: Among patients with co-existing T2D and CHB, SGLT2i use was associated with a lower risk of incident HCC.
引用
收藏
页码:1569 / 1580
页数:12
相关论文
共 62 条
  • [1] The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
    Akinyemiju, Tomi
    Abera, Semaw
    Ahmed, Muktar
    Alam, Noore
    Alemayohu, Mulubirhan Assefa
    Allen, Christine
    Al-Raddadi, Rajaa
    Alvis-Guzman, Nelson
    Amoako, Yaw
    Artaman, Al
    Ayele, Tadesse Awoke
    Barac, Aleksandra
    Bensenor, Isabela
    Berhane, Adugnaw
    Bhutta, Zulfiqar
    Castillo-Rivas, Jacqueline
    Chitheer, Abdulaal
    Choi, Jee-Young
    Cowie, Benjamin
    Dandona, Lalit
    Dandona, Rakhi
    Dey, Subhojit
    Dicker, Daniel
    Phuc, Huyen
    Ekwueme, Donatus U.
    Zaki, Maysaa El Sayed
    Fischer, Florian
    Furst, Thomas
    Hancock, Jamie
    Hay, Simon I.
    Hotez, Peter
    Jee, Sun Ha
    Kasaeian, Amir
    Khader, Yousef
    Khang, Young-Ho
    Kumar, G. Anil
    Kutz, Michael
    Larson, Heidi
    Lopez, Alan
    Lunevicius, Raimundas
    Malekzadeh, Reza
    McAlinden, Colm
    Meier, Toni
    Mendoza, Walter
    Mokdad, Ali
    Moradi-Lakeh, Maziar
    Nagel, Gabriele
    Nguyen, Quyen
    Nguyen, Grant
    Ogbo, Felix
    [J]. JAMA ONCOLOGY, 2017, 3 (12) : 1683 - 1691
  • [2] GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis
    Amann, Thomas
    Maegdefrau, Ulrike
    Hartmann, Arndt
    Agaimy, Abbas
    Marienhagen, Joerg
    Weiss, Thomas S.
    Stoeltzing, Oliver
    Warnecke, Christina
    Schoelmerich, Juergen
    Oefner, Peter J.
    Kreutz, Marina
    Bosserhoff, Anja K.
    Hellerbrand, Claus
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (04) : 1544 - 1552
  • [3] ANDERSON BB, 1992, J NATL MED ASSOC, V84, P129
  • [4] Hepatitis B virus and hepatocellular carcinoma
    Arbuthnot, P
    Kew, M
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2001, 82 (02) : 77 - 100
  • [5] The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
    Arvanitakis, Konstantinos
    Koufakis, Theocharis
    Kotsa, Kalliopi
    Germanidis, Georgios
    [J]. PHARMACOLOGICAL RESEARCH, 2022, 181
  • [6] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    [J]. LANCET, 2021, 398 (10296) : 262 - 276
  • [7] Five-year stability of ICD-10 diagnoses among Chinese patients presented with first-episode psychosis in Hong Kong
    Chang, Wing Chung
    Pang, Shirley Lai Kwan
    Chung, Dicky Wai Sau
    Chan, Sandra Sau Man
    [J]. SCHIZOPHRENIA RESEARCH, 2009, 115 (2-3) : 351 - 357
  • [8] Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Chehrehgosha, Haleh
    Sohrabi, Masoud Reza
    Ismail-Beigi, Faramarz
    Malek, Mojtaba
    Babaei, Mohammad Reza
    Zamani, Farhad
    Ajdarkosh, Hossein
    Khoonsari, Mahmood
    Fallah, Afshin Eshghi
    Khamseh, Mohammad E.
    [J]. DIABETES THERAPY, 2021, 12 (03) : 843 - 861
  • [9] Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study
    Cheung, Ka Shing
    Chan, Esther W.
    Wong, Angel Y. S.
    Chen, Lijia
    Seto, Wai Kay
    Wong, Ian C. K.
    Leung, Wai K.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (07): : 743 - 749
  • [10] Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
    Cheung, Ka Shing
    Chan, Esther W.
    Wong, Angel Y. S.
    Chen, Lijia
    Wong, Ian C. K.
    Leung, Wai Keung
    [J]. GUT, 2018, 67 (01) : 28 - 35